Gallant closes $18 million Series B to advance its stem cell therapies for pets, led by Digitalis Ventures.

Jun 30, 2025•6 months ago

Amount Raised

$18 Million

Round Type

series b

San DiegoBiotechnology

Investors

Nova Quest Capital ManagementHill Creek PartnersBold CapitalDigitalis Ventures

Description

Gallant, an animal health biotechnology company, successfully closed its $18 million Series B financing round. The funding, led by Digitalis Ventures, will accelerate the commercial rollout of its lead product targeting Feline Chronic Gingivostomatitis. This funding also supports a pipeline of therapies for other common diseases in pets. Gallant aims to address the underlying issues rather than merely managing symptoms.

Company Information

Company

Gallant

Location

10865 Road to the Cure, Ste 101

San Diego, California, United States

About

Gallant is a regenerative medicine company pioneering veterinary therapies that restore health at the source. We’re developing a pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies to address chronic conditions in dogs and cats—including feline chronic gingivostomatitis (FCGS), osteoarthritis, chronic kidney disease, and atopic dermatitis. Our first product, based on a proprietary uterine-derived stem cell platform, is on track for conditional FDA approval in 2026. Led by industry pioneers in veterinary regenerative medicine, Gallant combines science, purpose, and compassion to help pets live healthier, more vibrant lives.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends